Proteomic analysis reveals brain Rab35 as a potential biomarker of mitragynine withdrawal in rats
Hassan R, Othman N, Mansor SM, Müller CP, Hassan Z (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 172
Pages Range: 139-150
DOI: 10.1016/j.brainresbull.2021.04.018
Abstract
Mitragyna speciosa, also known as kratom, has been used for mitigating the severity of opioid withdrawal in humans. Its main indole alkaloid, mitragynine, has been considered as a pharmacotherapy for pain conditions and opioid replacement therapy. However, at high doses, chronic mitragynine may also have an addiction potential. The effects of chronic action of mitragynine in the brain are still unknown. The present study developed a mitragynine withdrawal model in rats and used it for a proteomic analysis of mitragynine withdrawal effects. Mitragynine (30 mg/kg, i.p.) was administered daily over a period of 14 days and then withdrawn. A proteomic analysis revealed that from a total of 1524 proteins identified, 31 proteins were upregulated, and 3 proteins were downregulated in the mitragynine withdrawal model. The Rab35 protein expression increased most profoundly in the mitragynine withdrawal group as compared to vehicle group. Therefore, it is proposed that Rab35 in the brain might be considered as a potential biomarker during mitragynine withdrawal and might be valuable target protein in developing new pharmacotherapies in the future.
Authors with CRIS profile
Involved external institutions
Malaysia (MY)How to cite
APA:
Hassan, R., Othman, N., Mansor, S.M., Müller, C.P., & Hassan, Z. (2021). Proteomic analysis reveals brain Rab35 as a potential biomarker of mitragynine withdrawal in rats. Brain Research Bulletin, 172, 139-150. https://doi.org/10.1016/j.brainresbull.2021.04.018
MLA:
Hassan, Rahimah, et al. "Proteomic analysis reveals brain Rab35 as a potential biomarker of mitragynine withdrawal in rats." Brain Research Bulletin 172 (2021): 139-150.
BibTeX: Download